What is the recommended management for a patient with painful buttock swelling after an intramuscular injection (possible Nicolau syndrome)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Nicolau Syndrome After Intramuscular Injection

For a patient presenting with painful buttock swelling after an intramuscular injection concerning for Nicolau syndrome, immediately initiate conservative management with analgesics, prophylactic antibiotics, and antithrombotic therapy while avoiding surgical intervention unless necrosis is established. 1

Immediate Recognition and Assessment

Nicolau syndrome presents with severe pain at the injection site (often during or immediately after injection), followed by edema, erythema, and characteristic livedoid (net-like) discoloration of the skin that progresses to ischemic necrosis of skin, soft tissue, and potentially muscle 1, 2. The buttock is the most common site given frequent intramuscular injections in this location 3, 4.

Key diagnostic features to identify:

  • Severe pain disproportionate to examination findings, beginning during or within hours of injection
  • Progressive skin discoloration with livedoid pattern (reticular, net-like appearance)
  • Edema and induration at injection site
  • Timeline: symptoms typically evolve over 24-48 hours post-injection

Rule out alternative diagnoses including infection (abscess), pressure necrosis, and vascular complications. Imaging with duplex sonography can identify vascular involvement, and radiography should exclude foreign bodies like broken needles 5.

Initial Conservative Management

The cornerstone of early treatment is medical management, not surgical intervention:

  1. Analgesics: Administer appropriate pain control. NSAIDs like naproxen 500 mg BID or meloxicam 7.5-15 mg daily can be used 6, though avoid intramuscular administration of any medications 7, 8.

  2. Prophylactic antibiotics: Initiate broad-spectrum coverage effective against aerobic and anaerobic organisms 1. While Nicolau syndrome itself is not infectious, secondary infection is a risk with tissue necrosis 5.

  3. Antithrombotic therapy: Administer enoxaparin or similar agents to address the microvascular thrombosis component 2. Consider adding cilostazol 2.

  4. Local wound care: Keep the area clean with topical bacitracin and monitor closely 9.

  5. Elevation and warmth: If vascular compromise extends distally (e.g., dusky toes), elevate the affected limb and apply warm compresses to the contralateral side to promote collateral circulation 9.

Hyperbaric Oxygen Therapy

Consider hyperbaric oxygen therapy (HBOT) as an adjunctive treatment, particularly for established necrotic ulcers. A recent case demonstrated complete healing after 30 HBOT sessions in a patient with NS from etofenamate injection 10. HBOT enhances tissue oxygenation and promotes wound healing in ischemic tissue.

Surgical Management

Reserve surgical debridement only for established necrosis after the acute phase has evolved 3. Premature surgical intervention may worsen outcomes. When necrosis is clearly demarcated:

  • Perform surgical debridement of necrotic tissue
  • Insert drains if needed
  • Approximate viable skin edges
  • Continue antibiotics for approximately 2 weeks
  • Maintain daily sterile dressings 3

One case required 185 days of wound care with multiple debridements before achieving 100% epithelialization 4, highlighting the prolonged healing timeline.

Critical Prevention Considerations

The intramuscular route should be avoided in postoperative pain management 7 and is not recommended for routine medication administration when alternatives exist 8. When intramuscular injections are necessary:

  • Use proper injection technique with appropriate needle length (4 mm for subcutaneous, avoiding intramuscular when possible) 11, 12
  • Inject slowly to avoid vascular injury
  • Avoid injection into areas with visible vessels
  • The buttocks have abundant subcutaneous tissue but remain a common site for NS 13, 12
  • Never inject medications with known vasoconstrictive or irritant properties intramuscularly

Expected Outcomes

Complete healing is achievable but may take weeks to months, typically leaving hypopigmented scarring 10, 1. Early recognition and comprehensive conservative management significantly improve outcomes 1. The key is recognizing the syndrome early—severe pain during or immediately after injection should raise immediate suspicion.

Common pitfall: Do not mistake early NS for simple injection site reaction or abscess. The characteristic severe pain and rapid progression to livedoid discoloration within 24-48 hours distinguishes NS from infectious processes, which typically evolve more slowly and lack the distinctive reticular skin pattern.

References

Research

[Nicolau syndrome].

Medicina, 2023

Research

Nicolau Syndrome in an Extremely Premature Neonate: A Case Report.

Advances in neonatal care : official journal of the National Association of Neonatal Nurses, 2026

Guideline

new insulin delivery recommendations.

Mayo Clinic Proceedings, 2016

Guideline

insulin administration.

Diabetes Care, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.